You are here

Herbert Smith Freehills advises sponsors on Yunkang Group's Hong Kong IPO / 史密夫斐尔律师事务所作为保荐人律师为云康集团香港上市提供法律服务

18 May 2022 | China
News

Share

Leading international law firm Herbert Smith Freehills has advised CMB International Capital Limited and SPDB International Capital Limited as joint sponsors of medical operation services provider Yunkang Group Limited (02325.HK)’s listing on the Main Board of the Hong Kong Stock Exchange.

Yunkang Group offers a full suite of diagnostic testing services for medical institutions. According to Frost & Sullivan, Yunkang Group holds a market share of 3.7% and 12.5% respectively in medical operation service and diagnostic testing services for medical institution alliances in China in terms of revenue for 2020.

Yunkang Group listed on 18 May 2022.

"We are delighted to have worked with Yunkang Group, one of the leading diagnostic testing specialists on its successful listing on the Hong Kong Stock Exchange,” said Hong Kong partner Matt Emsley. "We congratulate the company and the joint sponsors on this successful IPO."

Herbert Smith Freehills has advised on a number of biotech listings since the Hong Kong exchange introduced its new regime for biotech listings in 2018, including those of Shanghai Junshi Biosciences (01877.HK), TOT BIOPHARM (01875.HK), SinoMab BioScience Limited (03681.HK), Peijia Medical (09996.HK), Antengene Corporation Limited (06996.HK), CARsgen Therapeutics (02171.HK), Brii Biosciences (02137.HK), Shanghai HeartCare Medical Technology (06609.HK), Acotec Scientific Holdings Limited (06669.HK), and Abbisko Cayman Limited (02256.HK), Shanghai Bio-heart (02185.HK), and Lepu Biopharma (02157.HK).

"We have advised extensively on Chinese companies seeking listings in Hong Kong, and we look forward to continuing supporting issuers and sponsors on their fundraising activities," said Herbert Smith Freehills Kewei joint operation partner Stanley Xie.

In the past six months, Herbert Smith Freehills and Kewei have advised on five successful listings in Hong Kong, ranking second among 34 international and local firms in Hong Kong, according to Ryanben Capital.

Partners Matt, Stanley and Jin Kong jointly led the team advising the joint sponsors, assisted by senior associate Kris Cheung, associates Sean Ji, Kaiwen Sun and Sean Gao, legal assistant Ting Wang and trainee solicitor Ken Yeung.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the listing.

全球领先的律师事务所史密夫斐尔于医学运营服务提供商云康集团有限公司(02325.HK)在香港联交所主板上市的项目中担任联席保荐人招银国际和浦银国际的律师并提供法律服务。

云康集团为医疗机构提供全套的诊断检测服务。根据弗若斯特沙利文,于2020年,按收益计云康集团于中国医学运营服务市场的市场份额为3.7%;为医联体提供诊断检测服务市场的市场份额为12.5%。

云康集团的股份于2022年5月18日开始在香港联交所交易。

史密夫斐尔香港办公室合伙人艾迈修(Matt Emsley)表示:“云康集团是诊断检测服务领域的领先公司之一,我们非常荣幸为其在联交所上市提供助力。我们衷心向云康集团和联席保荐人表示祝贺。”

史密夫斐尔已经为众多医疗行业公司在香港上市提供法律服务,包括君实生物(01877.HK)、东曜药业(01875.HK)、中国抗体(03681.HK)、沛嘉医疗(09996.HK)、德琪医药(06996.HK)、科济药业(02171.HK)、腾盛博药(02137.HK)、心玮医疗(06609.HK)、先瑞达医疗(06669.HK)、和誉开曼(02256.HK)、百心安(02185.HK)以及乐普生物(02157.HK)。

科伟史密夫斐尔联营办公室合伙人谢守德表示:“我们在服务中国公司于港上市方面经验丰富,期待继续为发行人和保荐人就融资活动提供支持。”

根据瑞恩资本(Ryanben Capital)的数据,本所在过去六个月里为5家公司在香港上市提供法律服务,在香港34家国际和本土律所中名列第二。

合伙人艾迈修、谢守德和孔瑾率领律师团队为此次上市的联席保荐人提供法律服务。主要团队成员包括张昕(Senior Associate)、季晓源(Associate)、孙凯文(Associate)、高炜华(Associate)、王婷(Legal Assistant)和杨恪行(Trainee Solicitor)。

金燊(Legal Manager)率领的科伟史密夫斐尔联营办公室替代性法律服务(ALT)联合团队在上市项目期间为招股书验证及其他文件密集型工作提供高效率的解决方案。

See how we help our clients in

Equity Capital Markets

Learn More

Media Contact

For further information on this news article, please contact:

Sally Greig, Head of Communications, Asia

Hong Kong
Tel: 
+852 21014624

VIVIAN HUANG, COMMUNICATIONS MANAGER, CHINA

Beijing
Tel: 
+86 10 65355025